No Data
Kanion Pharma to Trial Guben Xiaozhan Granules
Kanion Pharma's Unit to Trial Vascular Dementia Drug
Jiangsu Kanion Pharmaceutical (600557.SH): The new clinical trial for the indication of vascular dementia for epimedium flavonoid capsules has been approved.
Jiangsu Kanion Pharmaceutical (600557.SH) announced that its holding subsidiary Jiangsu Kanion Sunshine Pharmaceutical Co., Ltd. (“...
Jiangsu Kanion Pharmaceutical (600557.SH): Received the clinical trial approval notification for the Gu Ben Xiao Zhen granules.
On March 4, Gelonghui reported that Jiangsu Kanion Pharmaceutical (600557.SH) announced it has recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the Gu Ben Xiao Zhen granules. The prescription for Gu Ben Xiao Zhen granules is derived from clinical experience. Its functions and indications are to invigorate Qi, warm Yang, dispel wind, and fortify the exterior. It is used for chronic spontaneous urticaria with a deficiency in stabilizing the exterior.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
While Shareholders of Jiangsu Kanion PharmaceuticalLtd (SHSE:600557) Are in the Red Over the Last Year, Underlying Earnings Have Actually Grown
Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
